NeoGenomics Statistics
Total Valuation
NeoGenomics has a market cap or net worth of $1.85 billion. The enterprise value is $2.08 billion.
| Market Cap | 1.85B |
| Enterprise Value | 2.08B |
Important Dates
The next confirmed earnings date is Monday, July 29, 2024, after market close.
| Earnings Date | Jul 29, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NeoGenomics has 127.71 million shares outstanding. The number of shares has increased by 0.87% in one year.
| Shares Outstanding | 127.71M |
| Shares Change (YoY) | +0.87% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 1.25% |
| Owned by Institutions (%) | 102.66% |
| Float | 126.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 222.22 |
| PS Ratio | 3.03 |
| Forward PS | 2.74 |
| PB Ratio | 2.01 |
| P/FCF Ratio | n/a |
| PEG Ratio | 3.02 |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.40 |
| EV / EBITDA | 1,565.95 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.48, with a Debt / Equity ratio of 0.66.
| Current Ratio | 7.48 |
| Quick Ratio | 6.85 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | 458.66 |
| Debt / FCF | n/a |
| Interest Coverage | -8.05 |
Financial Efficiency
Return on equity (ROE) is -8.90% and return on invested capital (ROIC) is -6.74%.
| Return on Equity (ROE) | -8.90% |
| Return on Assets (ROA) | -5.00% |
| Return on Capital (ROIC) | -6.74% |
| Revenue Per Employee | $290,792 |
| Profits Per Employee | -$40,111 |
| Employee Count | 2,100 |
| Asset Turnover | 0.37 |
| Inventory Turnover | 15.88 |
Taxes
| Income Tax | -6.82M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -18.71% in the last 52 weeks. The beta is 1.18, so NeoGenomics's price volatility has been higher than the market average.
| Beta (5Y) | 1.18 |
| 52-Week Price Change | -18.71% |
| 50-Day Moving Average | 14.06 |
| 200-Day Moving Average | 15.27 |
| Relative Strength Index (RSI) | 54.19 |
| Average Volume (20 Days) | 725,424 |
Short Selling Information
| Short Interest | 5.51M |
| Short Previous Month | 6.07M |
| Short % of Shares Out | 4.32% |
| Short % of Float | 4.38% |
| Short Ratio (days to cover) | 7.38 |
Income Statement
In the last 12 months, NeoGenomics had revenue of $610.66 million and -$84.23 million in losses. Loss per share was -$0.66.
| Revenue | 610.66M |
| Gross Profit | 255.26M |
| Operating Income | -103.23M |
| Pretax Income | -91.06M |
| Net Income | -84.23M |
| EBITDA | 1.33M |
| EBIT | -81.00M |
| Loss Per Share | -$0.66 |
Balance Sheet
The company has $384.83 million in cash and $608.18 million in debt, giving a net cash position of -$223.35 million or -$1.75 per share.
| Cash & Cash Equivalents | 384.83M |
| Total Debt | 608.18M |
| Net Cash | -223.35M |
| Net Cash Per Share | -$1.75 |
| Equity (Book Value) | 923.41M |
| Book Value Per Share | 7.23 |
| Working Capital | 497.19M |
Cash Flow
In the last 12 months, operating cash flow was -$15.18 million and capital expenditures -$24.41 million, giving a free cash flow of -$39.59 million.
| Operating Cash Flow | -15.18M |
| Capital Expenditures | -24.41M |
| Free Cash Flow | -39.59M |
| FCF Per Share | -$0.31 |
Margins
Gross margin is 41.80%, with operating and profit margins of -16.90% and -13.79%.
| Gross Margin | 41.80% |
| Operating Margin | -16.90% |
| Pretax Margin | -14.91% |
| Profit Margin | -13.79% |
| EBITDA Margin | 0.22% |
| EBIT Margin | -13.26% |
| FCF Margin | -6.48% |
Dividends & Yields
NeoGenomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.87% |
| Shareholder Yield | -0.87% |
| Earnings Yield | -4.55% |
| FCF Yield | -2.14% |
Analyst Forecast
The average price target for NeoGenomics is $19.78, which is 36.32% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.78 |
| Price Target Difference | 36.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on April 16, 2003. It was a reverse split with a ratio of 1:100.
| Last Split Date | Apr 16, 2003 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
NeoGenomics has an Altman Z-Score of 1.89 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.89 |
| Piotroski F-Score | 4 |